BOARD OF DIRECTORS

Troy Wilson, Ph.D., J.D.

Chairman

Troy E. Wilson, Ph.D., J.D., is one of Kura’s co-founders and has served as President, CEO and Chairman of Kura’s Board of Directors since inception in August 2014. He also co-founded Avidity Biosciences (NASDAQ: RNA) and has served as Chairman of its Board of Directors since its inception in 2013. Previously, he co-founded and served as President and CEO of Araxes Pharma LLC and Wellspring Biosciences, Inc., where his team pioneered the discovery and development of small molecules inhibitors of the KRAS oncoprotein. Earlier in his career, Dr. Wilson co-founded and served as President and CEO of Intellikine, a private biopharmaceutical company, acquired by Takeda Pharmaceutical Company Limited in 2011, and he co-founded and served as Chief Business Officer of Ambrx (NASDAQ: AMAM), acquired by Johnson & Johnson Innovative Medicines in 2024. He serves as a director of Puma Biotechnology and Cartography Biosciences. Dr. Wilson holds a law degree from New York University and graduated with a Ph.D. in bioorganic chemistry and a B.A. in biophysics from the University of California, Berkeley.